Defiance Daily Target 2X Long Mrna ETF (MRNX) closed at $208.20 on November 6, 2026, up 10.4% from the previous close, on volume of 252,666 shares (30-day average 229,861).
Data as of November 6, 2026.
No headlines found.
No press releases found.
No news found.
The Defiance Daily Target 2X Long MRNA ETF (MRNX) provides investors with amplified long exposure to Moderna, Inc. (NASDAQ: MRNA), a biotechnology company focused on the development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Because the Fund seeks daily leveraged investment results, it is very different from most other exchange-traded funds. It is also riskier than alternatives that do not use leverage. The Fund seeks daily investment results, before fees and expenses, of two times (200%) the daily percentage change in the share price of Moderna, Inc. (NASDAQ: MRNA). The Fund does not seek to achieve its stated investment objective for a period other than a single trading day. The Fund is an actively managed exchange traded fund ("ETF") that attempts to achieve two times (200%) the daily percentage change in the share price of the Underlying Security by employing derivatives, namely swap agreements and/or listed options contracts.
Defiance Daily Target 2X Long Mrna ETF trades on the ARCA stock market under the symbol MRNX.
As of November 6, 2026, MRNX stock price climbed to $208.20 with 252,666 million shares trading.
MRNX has a beta of 2.09, meaning it tends to be more sensitive to market movements. MRNX has a correlation of 0.02 to the broad based SPY ETF.
MRNX has a market cap of $33.31 million. This is considered a Sub-Micro Cap stock.
MRNX support price is $163.33 and resistance is $213.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRNX shares will trade within this expected range on the day.
